Friday, 22 Jun 2018

You are here

Medicare Drug Prices Jump Ten Times the Inflation Rate

CNN reports that a new congressional analysis of Medicare drug pricing shows the prices of the 20 most commonly prescribed brand-name drugs have risen nearly 10 times the annual rate of inflation in the past five years. (Citation source: http://bit.ly/2pInEnq)

The report entitled, "Manufactured Crisis: How devastating drug price increases are harming America's seniors," was authored by Sen. Claire McCaskill, D-Missouri, who has been investigating escalating drug prices in the past year.

There is growing concern by McCaskil and others in congress over rising drug costs and its impact on the health and finances of an aging US population. 

The report examined the costs of the 20 most-prescribed drugs under the Medicare Part D program from 2012 to 2017. In this 5 year span the cost of common drugs skyrocketed:

  • Nitrostat, had the largest percentage change of 477%.
  • Zostavax, had the lowest percentage increase but still increased 31% over five years.
  • 12/20 drugs had price increases of > 50% and 6/20 had price increases > 100% over the last 5 years.
  • Prices increased for every brand-name drug of the top 20 most-prescribed brand-name drugs for seniors in the last five years. On average, prices for these drugs increased 12 percent every year for the last five years—approximately ten times higher than the average annual rate of inflation.
  • Even with 48 million fewer prescriptions (of the top 20 drugs) between 2012 to 2017, total sales increased by almost $8.5 billion.

By law, Medicare is not allowed to directly negotiate drug prices, which critics say results in the government spending tens of billions of dollars unnecessarily. Democrats have long pushed for Medicare to be able to negotiate on pricing, while Republicans have opposed such measures.

President Trump has vowed to "make fixing the injustice of high drug prices one of our top priorities."

 

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

EULAR 2018 - Day 3 Report

Day 3 highlights include Behcet’s responds to apremilast and that biologics do not differentially affect TKR/THR post-operative infection rates. Be sure to check out today's podcast as well. 

Canada Closer to Marijuana Approval

Reuters reports that Canada’s Senate on Thursday voted to legalize recreational marijuana, clearing a major hurdle that puts the country on track to become the first Group of Seven nation to permit national use of the drug.

Now the law and amendments go to the House of Commons who will need to decide on before the law can be passed.

Advance Practice Clinicians Proliferating in Specialty Practices

An analysis of SK&A outpatient provider files, covering 90% of physician practices in the United States, shows that between 2008 to 2016, there was a 22% increase in the employment of advanced practice clinicians (APCs) by specialty practices.  By 2016, 28% of all specialty practices employed APCs.

Trump Blasts Drug Makers on the Price of Drugs

Reuter's reports Friday that President Donald Trump blasted drugmakers and healthcare “middlemen” for making prescription drugs unaffordable for Americans. Nonetheless, many healthcare stocks rose as it became clear the administration had avoided taking aggressive and direct measures to cut drug prices.

Here are many New Sources on this developing story:

Patients May Not Fill Your Prescription

A new study linking administrative claims and electronic health records (EHRs) shows that nearly 40% of patients fill and take newly prescribed methotrexate (MTX), tofacitinib or biologics. 

Kan et al set out to estimate the extent and predictors of primary nonadherence in rheumatoid arthritis (RA) patients who received new prescriptions for methotrexate, biologics or tofacitinib.